Why AbbVie (ABBV) Stock Is Worth To Buy?
ABBV has formulated a long-term plan, namely Rinvoq and Skyrizi two drugs.
www.investreader.com - April 17, 2021
ABBV Stock: Why Is AbbVie Stock Worth Watching?
The company's two new drug application are waiting for approval by FDA.
www.investreader.com - April 04, 2021
Is It Too Late to Buy AbbVie Stock? | The Motley Fool
In a market where many stocks look overvalued, this company has proven that there are still bargains to be found.
www.fool.com - February 21, 2021
AbbVie shares continue to trade in a bull market after better than expected Q4 results | Invezz
AbbVie (NYSE: ABBV) shares weakened last week by more than 3%, and the current price stands around $104. According to analysts, it’s not hard to find reasons to invest in AbbVie, and as long the price is above $90, there is no risk of the trend reversal. Fundamental analysis: Total revenue has increased 59.3% in […]
invezz.com - February 13, 2021
AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod
AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.
www.zacks.com - February 11, 2021
ABBV: Why AbbVie Stock Could be Headed Lower | StockNews.com
AbbVie Inc.(NYSE:ABBV): A head and shoulders pattern has formed in the chart of AbbVie. When this happens, a down move is expected. Read more to learn how to profit from this trade.
stocknews.com - February 11, 2021
Here's Why Investors Liked AbbVie's Q4 Results | The Motley Fool
Better-than-expected top and bottom lines plus positive guidance were exactly what Wall Street wanted.
www.fool.com - February 03, 2021
AbbVie (ABBV) Q4 Earnings and Revenues Surpass Estimates
AbbVie (ABBV) delivered earnings and revenue surprises of 2.46% and 0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
www.zacks.com - February 03, 2021